Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts

J Infect Dis. 2022 Jan 18;225(2):238-242. doi: 10.1093/infdis/jiab537.

Abstract

Human babesiosis caused by Babesia microti can be fatal in immunocompromised patients, and the currently used drugs are often ineffective. A recent study found that clofazimine clears B. microti Munich strain in immunocompromised mice. In the present study, we investigated the efficacies of clofazimine and 2-drug combinations involving clofazimine, atovaquone, and azithromycin against B. microti Peabody mjr strain in immunocompromised mice. Treatment with clofazimine alone, clofazimine plus azithromycin, and atovaquone plus azithromycin was ineffective and failed to eliminate the parasites completely, while a 44-day treatment with clofazimine plus atovaquone was highly effective and resulted in a radical cure.

Keywords: Babesia microti; atovaquone; azithromycin; clofazimine; combination therapy; immunocompromised mice; radical cure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Antiprotozoal Agents / therapeutic use*
  • Atovaquone / therapeutic use*
  • Azithromycin / therapeutic use*
  • Babesia microti / drug effects*
  • Babesia microti / genetics
  • Babesia microti / isolation & purification
  • Babesiosis / drug therapy*
  • Babesiosis / immunology
  • Clofazimine / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Immunocompromised Host
  • Mice

Substances

  • Anti-Bacterial Agents
  • Antiprotozoal Agents
  • Azithromycin
  • Clofazimine
  • Atovaquone